{
    "clinical_study": {
        "@rank": "23469", 
        "acronym": "COPTER", 
        "arm_group": [
            {
                "arm_group_label": "smokers on dual antiplatelet therapy with ASA and Prasugrel", 
                "arm_group_type": "Experimental", 
                "description": "All patients  quit smoking for a 2 weeks period"
            }, 
            {
                "arm_group_label": "smokers on dual antiplatelet therapy with ASA and ticagrelor", 
                "arm_group_type": "Experimental", 
                "description": "All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period"
            }, 
            {
                "arm_group_label": "smokers on dual antiplatelet therapy with ASA and Clopidogrel", 
                "arm_group_type": "Active Comparator", 
                "description": "All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period"
            }
        ], 
        "brief_summary": {
            "textblock": "All consecutive patients undergone PTCA in the period between July 2013 and December 2013\n      are eligible to be enrolled. Study population are divided in :\n\n      Group 1: smokers on dual antiplatelet therapy with ASA (100 mg once a day) and Prasugrel (10\n      mg die); Group 2: smokers on dual antiplatelet therapy with ASA(100 mg once a day)  and\n      Ticagrelor (90 mg twice a day); Control group: smokers on dual antiplatelet therapy with\n      ASA(100 mg once a day)   and Clopidogrel (75 mg once a day).\n\n      Platelet function is evaluated using a validated method: the VerifyNow System (Accumetrics\n      Inc., San Diego, CA), which is a point-of-care turbidimetry-based optical detection system\n      that measures platelet-induced aggregation. These value are measured Platelet function,\n      measured with the VerifyNow P2Y12. All patients on chronic dual antiplatelet therapy (>1\n      month) quit smoking for a 2 weeks period. Therefore PRU values are obtained at baseline (at\n      the enrollment time) and after 2 weeks after smoking cessation. Platelet reactivity are\n      expressed in P2Y12 reaction  units (PRU). PRU values >240 are suggestive of high platelet\n      reactivity.\n\n      Primary outcomes: P2Y12 reaction units (PRU) at baseline and two weeks after quitting\n      smoking."
        }, 
        "brief_title": "Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Smoking", 
                "Acute Coronary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "All consecutive patients undergone PTCA in the period between July 2013 and December 2013\n      are eligible to be enrolled. Study population are divided in :\n\n      Group 1: smokers on dual antiplatelet therapy with ASA (100 mg once a day) and Prasugrel (10\n      mg die); Group 2: smokers on dual antiplatelet therapy with ASA(100 mg once a day)  and\n      Ticagrelor (90 mg twice a day); Control group: smokers on dual antiplatelet therapy with\n      ASA(100 mg once a day)   and Clopidogrel (75 mg once a day).\n\n      Platelet function is evaluated using a validated method: the VerifyNow System (Accumetrics\n      Inc., San Diego, CA), which is a point-of-care turbidimetry-based optical detection system\n      that measures platelet-induced aggregation. These value are measured Platelet function,\n      measured with the VerifyNow P2Y12. All patients on chronic dual antiplatelet therapy (>1\n      month) quit smoking for a 2 weeks period. Therefore PRU values are obtained at baseline (at\n      the enrollment time) and after 2 weeks after smoking cessation. Platelet reactivity are\n      expressed in P2Y12 reaction  units (PRU). PRU values >240 are suggestive of high platelet\n      reactivity.\n\n      Primary outcomes: P2Y12 reaction units (PRU) at baseline and two weeks after quitting\n      smoking."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All consecutive patients undergone PTCA in our institution in the period between July\n             2013 and December 2013 will be eligible to be enrolled.\n\n          -  smokers will be all patients smoking 15\u00b110 cigarettes daily.\n\n          -  patients on dual antiplatelet therapy with ASA and P2Y12 inhibitors.\n\n          -  recent (<12 months) percutaneous coronary interventions\n\n          -  angiographically-proven coronary artery disease\n\n        Exclusion Criteria:\n\n        - people unable to understand and willing to sign the informed consent form"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026713", 
            "org_study_id": "WD-131213"
        }, 
        "intervention": {
            "arm_group_label": [
                "smokers on dual antiplatelet therapy with ASA and Prasugrel", 
                "smokers on dual antiplatelet therapy with ASA and ticagrelor", 
                "smokers on dual antiplatelet therapy with ASA and Clopidogrel"
            ], 
            "description": "evaluate the platelet reactivity  after 15 days by quit smoking", 
            "intervention_name": "quit smoking for a 2 weeks period", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 1, 2014", 
        "location": {
            "contact": {
                "email": "dott.mpolacco@gmail.com", 
                "last_name": "Marina Polacco", 
                "phone": "3333347960"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "state": "Roma"
                }, 
                "name": "Sapienza University of Rome"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "3", 
        "official_title": "\"Impact of Cigarette Smoking on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With P2Y12 Inhibitors\" - Trial COPTER -", 
        "overall_contact": {
            "email": "dott.mpolacco@gmail.com", 
            "last_name": "Marina Polacco", 
            "phone": "3333347960"
        }, 
        "overall_official": {
            "affiliation": "Sapienza University of Rome", 
            "last_name": "marina MD polacco, medicine", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Absolute changes in platelet reactivity (expressed as P2Y(12) reaction units by the point-of-care VerifyNow assay [Accumetrics, San Diego, California])", 
            "measure": "Assessment of platelet reaction units (PRU)", 
            "safety_issue": "No", 
            "time_frame": "after 2 weeks of quitting smoking"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026713"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Roma La Sapienza", 
            "investigator_full_name": "Polacco Marina", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Roma La Sapienza", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Roma La Sapienza", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}